Department of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.
Department of Nephrology, Saga University Internal Medicine, Japan.
Intern Med. 2024;63(3):461-464. doi: 10.2169/internalmedicine.1862-23. Epub 2024 Feb 1.
A 48-year-old woman visited our hospital because of bilateral lacrimal gland enlargement. Her serum immunoglobulin G4 (IgG4) level was high, and positron emission tomography-computed tomography showed significant positive findings in the bilateral lacrimal gland. A biopsy revealed a considerable increase in IgG4/CD138, leading to a diagnosis of IgG4-related dacryoadenitis. The disease did not respond to steroid therapy, so treatment was started with baricitinib because of exacerbation of the original atopic dermatitis and dacryoadenitis after the second dose of the coronavirus disease 2019 (COVID-19) vaccine. Baricitinib was effective for resolving both dermatitis and dacryoadenitis, and steroids were able to be discontinued. The IgG4 level also improved.
一位 48 岁女性因双侧泪腺肿大就诊于我院。其血清免疫球蛋白 G4(IgG4)水平升高,正电子发射断层扫描-计算机断层扫描(PET-CT)显示双侧泪腺有明显阳性发现。活检显示 IgG4/CD138 明显增加,最终诊断为 IgG4 相关泪腺炎。该疾病对类固醇治疗无反应,因此在第二次接种 2019 冠状病毒病(COVID-19)疫苗后,由于特应性皮炎和泪腺炎恶化,开始使用巴瑞替尼进行治疗。巴瑞替尼治疗有效,皮炎和泪腺炎均得到缓解,且可以停用类固醇。IgG4 水平也有所改善。